ProCE Banner Activity

My Take on Key Studies Presented at EULAR 2021 That Will Affect the Management of Patients With Axial Spondyloarthritis

Conference Coverage
Clinical Thought
Expert commentary on the key studies from EULAR 2021 on axial spondyloarthritis and axial psoriatic arthritis.

Released: August 26, 2021

Expiration: August 25, 2022

No longer available for credit.

Share

Faculty

Atul Deodhar

Atul Deodhar, MD

Professor of Medicine
Medical Director
, Rheumatology Clinics
Division of Arthritis and Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Janssen administered by Scientific Affairs

Faculty Disclosure

Primary Author

Atul Deodhar, MD

Professor of Medicine
Medical Director
, Rheumatology Clinics
Division of Arthritis and Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon

Atul Deodhar, MD: Advisory Board for AbbVie; Amgen; Boehringer Ingelheim; Bristol Myers Squibb; Celgene; Eli Lilly; GlaxoSmithKline; MoonLake; Novartis; Pfizer; and UCB. Consultant for AbbVie; Amgen; Boehringer Ingelheim; Bristol Myers Squibb; Celgene; Eli Lilly; GlaxoSmithKline; Novartis; Pfizer; and UCB. Contracted Research for AbbVie; Eli Lilly; GlaxoSmithKline; Novartis; Pfizer; and UCB.